Blog Post

In a major step forward for women’s health innovation, Midi Health has secured $50 million in Series C funding to expand its AI-powered healthcare platform focused on midlife women. At the heart of this expansion is an ambitious plan to build a dedicated women’s health search engine — an intelligent, medically vetted tool designed to support women navigating menopause, hormonal transitions, and long-term health planning. The funding will also fuel the growth of AgeWell, Midi’s new longevity care program, tailored specifically fro women over 40.

Meeting the Demand: The Rise of Midlife Women’s Health

Under‑served Population & Market Tailwinds

Women in perimenopause and menopause are often underserved by traditional healthcare systems: providers may lack training, symptoms may be dismissed, and searches on general medical sites can yield outdated or male‑biased results. Joanna Strober, Midi’s CEO, has criticized generic medical AI tools for surfacing stale or low-priority research. Midi aims to disrupt that by curating and vetting content specifically for women’s health. [Business Insider]

As hormone therapy, bone health, cardiovascular risk, mood, and metabolic shifts all become more relevant in midlife, the demand for personalized, evidence‑based guidance is rising. Employers, too, are beginning to include menopause and midlife care in benefit packages, further fueling demand.

Why Build Their Own AI Search Engine?

A domain‑specific search engine gives Midi two edges:

1. Domain expertise & vetting: Because the system is specialized, the team can prioritize the latest, highest-quality research in women’s health, reducing noise and misinformation.
   
   
2. Proprietary data & feedback loops: As users query and interact, Midi can gather usage signals, tailor ranking logic, and train models on domain‑relevant corpora — essentially evolving a specialized “women’s health knowledge graph.”
   
   

This is analogous to how startups like Your.MD pioneered AI health assistants by focusing on self-care and symptom triage.

Expanding Into Women‑Tailored Longevity Care: The AgeWell Program

Midi’s longevity arm, AgeWell, was launched in May 2025. The goal: to bring preventive, aging‑focused care firmly into the woman’s health spectrum — not as a luxury, but as a covered benefit under private insurance. Midi positions AgeWell as the first longevity offering optimized for women, covering diagnostics, monitoring, hormone balance, cardiovascular risk, bone health, brain health, and more.

Key differentiators of AgeWell:

• Insurance‑backed model: Unlike many “cash + boutique longevity” offerings, Midi’s AgeWell is structured to work with insurance, lowering cost barriers.
  
  
• Female‑centric approach: Many longevity solutions have historically targeted male “biohackers.” Midi claims a grounded, research‑driven roadmap tailored to women’s hormonal life stages.
  
  

This integration of midlife care + longevity signals a shift: rather than treating menopause as an endpoint, Midi treats it as a pivot into proactive, life‑course health.

What Challenges and Risks Lie Ahead?

While the vision is bold, there are several potential obstacles:

1. Data quality & bias
   Custom AI systems are only as good as their training data. Ensuring that the medical literature is current, inclusive (across racial/ethnic groups), and devoid of publication bias is nontrivial.
   
   
2. Regulation, medical safety, and liability
   Medical search tools face regulatory scrutiny (FDA, HIPAA, etc.). Curating health advice is fraught — the line between information and medical recommendation is thin.
   
   
3. Competition & moats
   Midi is entering a competitive landscape. Startups like Maven Clinic, Elektra Health, and larger incumbents (Amazon’s One Medical) are pushing into menopause and preventive care. On the longevity side, firms like Function Health (with broad preventive labs and scans) are gaining traction.
   
   
4. Adoption, trust, and provider training
   Many OB‑GYNs lack formal menopause training. Midi will need to scale its provider education/training to ensure quality care.
   
   
5. Sustainability and path to profitability
   Although Midi claims a $150M annual run rate (up from $60M at end‑2024) and plans a clear path to profitability, it is not yet profitable.
   
   

Strategic Implications & What This Means for the Global Health Tech Scene

For readers in the Global South, there are lessons to draw:

• Domain‑specific AI is powerful: Building health search engines tuned to population segments (e.g., women, adolescents, geriatrics) may yield better outcomes than general tools.
  
  
• Insured, scalable models matter: To reach lower-resource settings, a hybrid of insurance / government payers + digital scale is key.
  
  
• Localization & equity: A U.S.‑based model must be adapted for local contexts (differences in epidemiology, culture, health systems).
  
  
• Partnership opportunities: Midi’s approach suggests potential for collaborations with academic institutions, ministries of health, or NGOs to adapt AI tools for women’s health in underserved regions.

Conclusion

Midi Health’s $50 million funding round marks a pivotal moment not only for the company but for the broader future of women’s healthcare. By leveraging AI to create a dedicated, medically accurate search engine for women’s midlife health and expanding into insurance-backed longevity care, Midi is addressing long-overlooked gaps in both access and quality of care.

This model — combining personalized, tech-enabled care with scalability through insurance and digital delivery — offers a compelling blueprint for other health innovators, especially in regions like Sub-Saharan Africa, where women’s health remains under-resourced. The intersection of AI, gender-specific care, and longevity medicine opens new possibilities for equitable health systems around the world.